Abstract
A prothrombotic state may contribute to the elevated cardiovascular risk in patients with obstructive sleep apnea (OSA). We investigated the relationship between apnea severity and hemostasis factors and effect of continuous positive airway pressure (CPAP) treatment on hemostatic activity. We performed full overnight polysomnography in 44 OSA patients (mean age 47±10 years), yielding apnea–hypopnea index (AHI) and mean nighttime oxyhemoglobin saturation (SpO2) as indices of apnea severity. For treatment, subjects were double-blind randomized to 2 weeks of either therapeutic CPAP (n=18), 3 l/min supplemental nocturnal oxygen (n=16) or placebo–CPAP (<1 cm H2O) (n=10). Levels of von Willebrand factor antigen (VWF:Ag), soluble tissue factor (sTF), D-dimer, and plasminogen activator inhibitor (PAI)-1 antigen were measured in plasma pre- and posttreatment. Before treatment, PAI-1 was significantly correlated with AHI (r=0.47, p=0.001) and mean nighttime SpO2 (r=−0.32, p=0.035), but these OSA measures were not significantly related with VWF:Ag, sTF, and D-dimer. AHI was a significant predictor of PAI-1 (R 2=0.219, standardized β=0.47, p=0.001), independent of mean nighttime SpO2, body mass index (BMI), and age. A weak time-by-treatment interaction for PAI-1 was observed (p=0.041), even after adjusting for age, BMI, pre-treatment AHI, and mean SpO2 (p=0.046). Post hoc analyses suggested that only CPAP treatment was associated with a decrease in PAI-1 (p=0.039); there were no changes in VWF:Ag, sTF, and D-dimer associated with treatment with placebo–CPAP or with nocturnal oxygen. Apnea severity may be associated with impairment in the fibrinolytic capacity. To the extent that our sample size was limited, the observation that CPAP treatment led to a decrease in PAI-1 in OSA must be regarded as tentative.
Similar content being viewed by others
References
Hung J, Whitford EG, Parsons RW, Hillman DR (1990) Association of sleep apnoea with myocardial infarction in men. Lancet 336:261–264
Andreas S, Schulz R, Werner GS, Kreuzer H (1996) Prevalence of obstructive sleep apnoea in patients with coronary artery disease. Coron Artery Dis 7:541–545
Bassetti C, Aldrich MS (1999) Sleep apnea in acute cerebrovascular diseases: final report on 128 patients. Sleep 22:217–223
Dyken ME, Somers VK, Yamada T, Ren ZY, Zimmerman MB (1996) Investigating the relationship between stroke and obstructive sleep apnea. Stroke 27:401–407
Shahar E, Whitney CW, Redline S, Lee ET, Newman AB, Javier Nieto F, O’Connor GT, Boland LL, Schwartz JE, Samet JM (2001) Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med 163:19–25
Mooe T, Franklin KA, Holmstrom K, Rabben T, Wiklund U (2001) Sleep-disordered breathing and coronary artery disease: long-term prognosis. Am J Respir Crit Care Med 164:1910–1913
Peker Y, Hedner J, Kraiczi H, Loth S (2000) Respiratory disturbance index: an independent predictor of mortality in coronary artery disease. Am J Respir Crit Care Med 162:81–86
Saigo M, Hsue PY, Waters DD (2004) Role of thrombotic and fibrinolytic factors in acute coronary syndromes. Prog Cardiovasc Dis 46:524–538
Folsom AR (2001) Hemostatic risk factors for atherothrombotic disease: an epidemiologic view. Thromb Haemost 86:366–373
Shamsuzzaman AS, Gersh BJ, Somers VK (2003) Obstructive sleep apnea: implications for cardiac and vascular disease. JAMA 290:1906–1914
von Känel R, Dimsdale JE (2003) Hemostatic alterations in patients with obstructive sleep apnea and the implications for cardiovascular disease. Chest 124:1956–1967
Quan SF, Gersh BJ (2004) Cardiovascular consequences of sleep-disordered breathing: past, present and future: report of a workshop from the National Center on Sleep Disorders Research and the National Heart, Lung, and Blood Institute. Circulation 109:951–957
Wessendorf TE, Thilmann AF, Wang YM, Schreiber A, Konietzko N, Teschler H (2000) Fibrinogen levels and obstructive sleep apnea in ischemic stroke. Am J Respir Crit Care Med 162:2039–2042
Nobili L, Schiavi G, Bozano E, De Carli F, Ferrillo F, Nobili F (2000) Morning increase of whole blood viscosity in obstructive sleep apnea syndrome. Clin Hemorheol Microcirc 22:21–27
Reinhart WH, Oswald J, Walter R, Kuhn M (2002) Blood viscosity and platelet function in patients with obstructive sleep apnea syndrome treated with nasal continuous positive airway pressure. Clin Hemorheol Microcirc 27:201-207
Robinson GV, Pepperell JC, Segal HC, Davies RJ, Stradling JR (2004) Circulating cardiovascular risk factors in obstructive sleep apnoea: data from randomised controlled trials. Thorax 59:777–782
Geiser T, Buck F, Meyer BJ, Bassetti C, Haeberli A, Gugger M (2002) In vivo platelet activation is increased during sleep in patients with obstructive sleep apnea syndrome. Respiration 69:229–234
Hui DS, Ko FW, Fok JP, Chan MC, Li TS, Tomlinson B, Cheng G (2004) The effects of nasal continuous positive airway pressure on platelet activation in obstructive sleep apnea syndrome. Chest 125:1768–1775
Rangemark C, Hedner JA, Carlson JT, Gleerup G, Winther K (1995) Platelet function and fibrinolytic activity in hypertensive and normotensive sleep apnea patients. Sleep 18:188–194
Chin K, Ohi M, Kita H, Noguchi T, Otsuka N, Tsuboi T, Mishima M, Kuno K (1996) Effects of NCPAP therapy on fibrinogen levels in obstructive sleep apnea syndrome. Am J Respir Crit Care Med 153:1972–1976
Bokinsky G, Miller M, Ault K, Husband P, Mitchell J (1995) Spontaneous platelet activation and aggregation during obstructive sleep apnea and its response to therapy with nasal continuous positive airway pressure. A preliminary investigation. Chest 108:625–630
Sanner BM, Konermann M, Tepel M, Groetz J, Mummenhoff C, Zidek W (2000) Platelet function in patients with obstructive sleep apnoea syndrome. Eur Respir J 16:648–652
Bogdanov V, Balasubramanian V, Hathcock J, Vele O, Lieb M, Nemerson Y (2003) Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med 9:458–462
Meyer D, Girma JP (1993) von Willebrand factor: structure and function. Thromb Haemost 70:99–104
Lip GY, Lowe GD (1995) Fibrin D-dimer: a useful clinical marker of thrombogenesis? Clin Sci 89:205–214
Kohler HP, Grant PJ (2000) Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 342:1792–1801
Phillips BA, Schmitt FA, Berry DT, Lamb DG, Amin M, Cook YR (1990) Treatment of obstructive sleep apnea. A preliminary report comparing nasal CPAP to nasal oxygen in patients with mild OSA. Chest 98:325–330
Landsberg R, Friedman M, Ascher-Landsberg J (2001) Treatment of hypoxemia in obstructive sleep apnea. Am J Rhinol 15:311–313
Metropolitan Life Foundation (1983) Metropolitan height and weight tables. Stat Bull Metrop Insur Co 64:1
Lee KW, Lip GY (2003) Effects of lifestyle on hemostasis, fibrinolysis, and platelet reactivity: a systematic review. Arch Intern Med 163:2368–2392
Smith PL, Haponik EF, Bleecker ER (1984) The effects of oxygen in patients with sleep apnea. Am Rev Respir Dis 130:958–963
Farre R, Hernandez L, Montserrat JM, Rotger M, Ballester E, Navajas D (1999) Sham continuous positive airway pressure for placebo-controlled studies in sleep apnoea. Lancet 353:1154
Loredo JS, Ancoli-Israel S, Dimsdale JE (1999) Effect of continuous positive airway pressure vs placebo continuous positive airway pressure on sleep quality in obstructive sleep apnea. Chest 116:1545–1549
Rechtshaffen A, Kales A (1968) A manual of standardized terminology, techniques, and scoring system for sleep stages of human subjects. NIH, Washington, DC
Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B (1987) Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 2:3–9
Salomaa V, Stinson V, Kark JD, Folsom AR, Davis CE, Wu KK (1995) Association of fibrinolytic parameters with early atherosclerosis. The ARIC Study. Atherosclerosis Risk in Communities Study. Circulation 91:284–290
Eitzman DT, Westrick RJ, Xu Z, Tyson J, Ginsburg D (2000) Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery. Blood 96:4212–4215
Eren M, Painter CA, Atkinson JB, Declerck PJ, Vaughan DE (2002) Age-dependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1. Circulation 106:491–496
Milleron O, Pilliere R, Foucher A, de Roquefeuil F, Aegerter P, Jondeau G, Raffestin BG, Dubourg O (2004) Benefits of obstructive sleep apnoea treatment in coronary artery disease: a long-term follow-up study. Eur Heart J 25:728–734
Chin K, Kita H, Noguchi T, Otsuka N, Tsuboi T, Nakamura T, Shimizu K, Mishima M, Ohi M (1998) Improvement of factor VII clotting activity following long-term NCPAP treatment in obstructive sleep apnoea syndrome. QJM 91:627–633
Acknowledgements
Financial support was by NIH grants HL44915, AG08415, M01 RR00827, HL36005, and K23 HL04056-01.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
von Känel, R., Loredo, J.S., Ancoli-Israel, S. et al. Association between sleep apnea severity and blood coagulability: treatment effects of nasal continuous positive airway pressure. Sleep Breath 10, 139–146 (2006). https://doi.org/10.1007/s11325-006-0060-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11325-006-0060-3